Source: Annual Congress 2009 - Biological and clinical markers in lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
R. Zalacain, J. Algorta, N. Marina, A. Gomez, M. Uribarri, B. Calvo, S. Carrera, S. Pedrero, G. Lopez-Vivanco (Baracaldo, Zamudio, Spain). Potential diagnostic markers in bronquial fluid of patients with non small cell lung cancer (NSCLC). Eur Respir J 2009; 34: Suppl. 53, 2664

Member's Comments

No comment yet.

Related content which might interest you: Are there potential characteristical markers in bronquial fluid for diagnosis of small cell lung cancer (SCLC)? Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009 Small cell lung cancer in patients with elderly Source: Annual Congress 2007 - Therapy of lung cancer Year: 2007 Comparing exhaled molecular profiles of patients with non-small cell lung cancer (NSCLC) with those of patients with non-pulmonary malignancy Source: Annual Congress 2010 - Exhaled biomarkers: smells like disease Year: 2010 Predictors of radiation-induced lung toxicity in patients with locally advanced non small cell lung cancer (NSCLC): a retrospective analysis Source: Annual Congress 2009 - Management of thoracic malignancies Year: 2009 New cryobiopsy techniques influence the rate of diagnosis small cell lung cancer (SCLC) Source: Annual Congress 2010 - The role of endoscopy in the diagnosis of lung cancer Year: 2010 Cyclooxygenase(COX)-2 is over-expressed in non small cell lung cancer (NSCLC) and is a potential target for treatment Source: Eur Respir J 2002; 20: Suppl. 38, 400s Year: 2002 Staging with FDG-PET/CT influences stage-specific survival in non small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Imaging in oncology and infectious diseases Year: 2011 Evaluation of serum tumour markers in the lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 268s Year: 2002 Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer (ED SCLC) Source: International Congress 2019 – Treatment of lung cancer Year: 2019 Extrathoracic 18-FDG-PET uptakes in non small cell lung cancer (NSCLC) preoperative staging Source: Eur Respir J 2007; 30: Suppl. 51, 430s Year: 2007 Reflex testing  is crucial for treatment decisions in advanced non small cell lung cancer (NSCLC) Source: International Congress 2017 – Chinese Programme 2017 Year: 2017 Small cell lung cancer patients and their responses to treatment Source: Eur Respir J 2004; 24: Suppl. 48, 301s Year: 2004 Tumour infiltrating lymphocytes and tumour associated macrophages in chronic obstructive pulmonary disease (COPD) patients with non-small cell lung cancer (NSCLC) and in patients with NSCLC Source: Eur Respir J 2005; 26: Suppl. 49, 92s Year: 2005 Validation and comparison of several published prognostic systems for patients with small cell lung cancer Source: Eur Respir J 2011; 38: 657-663 Year: 2011 Quality indicators in lung cancer care-review of resection rates in early stage NSCLC (non small cell lung cancer) at King’s Source: International Congress 2018 – Lung cancer: risk factors, supportive measures and quality improvement Year: 2018 TTF-1 for prediction of response to chemotherapy in patients with locally advanced or metastatic small cell lung cancer (SCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Molecular signatures of non-small cell lung cancer (NSCLC) obtained from gene expression profiling of the benign bronchial mucosa of smokers with and without NSCLC Source: Annual Congress 2013 –Biology and molecular pathology of lung cancer Year: 2013 Characteristics and prognostic relevance of p53 gene mutations in Polish non small cell lung cancer (NSCLC) patients Source: Eur Respir J 2005; 26: Suppl. 49, 92s Year: 2005